Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Zika virus vaccine - IMV

Drug Profile

Research programme: Zika virus vaccine - IMV

Latest Information Update: 28 Oct 2020

At a glance

  • Originator Immunovaccine
  • Developer IMV
  • Class Synthetic vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Zika virus infection

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in Canada (Parenteral)
  • 03 May 2018 Immunovaccine is now called IMV
  • 15 Sep 2016 Preclinical trials in Zika virus infection (Prevention) in Canada (Parenteral)

Development Overview

Introduction

IMV (formerly Immunovaccine) is developing a viral vaccine, using its proprietary DepoVax™ technology, for the treatment of Zika virus infection. DepoVax™ is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a specific and sustained immune response with single-dose effectiveness. Preclinical development is underway in Canada.

In May 2018, Immunovaccine changed its name to IMV [1] .

As at October 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection (Prevention) in Canada (Parenteral).

Company Agreements

In April 2016, Immunovaccine and Leidos entered into a collaborative agreement to develop a vaccine against Zika virus infections. Under the terms of the agreement, Leidos will discover antigen candidates, utilising its Virtual Pharmaceutical Development Program, and Immunovaccine will formulate best of them in its DepoVax™ delivery system for preclinical testing [2] .

Key Development Milestones

Financing information

In June 2016, Immunovaccine reported closing of a bought deal private placement, from which net proceeds of $US8 002 500 will be used for progressing the development of the company's cancer and infectious vaccine candidates and also for general corporate and working capital purposes [3] .

Patent Information

The vaccine delivery formulation, DepoVax™, is patent protected [4] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Synthetic vaccines, Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Zika virus infection - Prevention No development reported (Preclinical) Canada Parenteral / unspecified IMV 28 Oct 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Immunovaccine Originator Canada
IMV Owner Canada
Leidos Holdings Collaborator USA

Development History

Event Date Update Type Comment
28 Oct 2020 Phase Change - No development reported No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in Canada (Parenteral) Updated 28 Oct 2020
03 May 2018 Company Involvement Immunovaccine is now called IMV Updated 17 May 2018
15 Sep 2016 Phase Change - Preclinical Preclinical trials in Zika virus infection (Prevention) in Canada (Parenteral) Updated 15 Sep 2016
07 Apr 2016 Licensing Status Immunovaccine and Leidos collaborate to develop Zika virus vaccine [2] Updated 19 Apr 2016
03 Mar 2016 Phase Change Early research in Zika virus infection in USA (Parenteral) Updated 19 Apr 2016
20 Jan 2015 Patent Information Immunovaccine has patent protection for DepoVax™ before January 2015 [4] Updated 11 Mar 2016

References

  1. Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq,Announces Reverse Stock Split.

    Media Release
  2. Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate.

    Media Release
  3. Immunovaccine Announces Closing of $8 Million Bought Deal Private Placement Financing.

    Media Release
  4. Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine.

    Media Release
Back to top